By ANNA EDNEY Four experimental cancer treatments that may one day help gravely ill children are facing review by U.S. pediatric advisers who have been working for years to find ways to develop more drugs for this underserved population. The medicines from GlaxoSmithKline Plc (GSK), Amgen (AMGN) Inc., Threshold Pharmaceuticals Inc. (THLD) and Boehringer Ingelheim…
There can be confusion and frustration when things we know to be true don’t necessarily mesh with the direction of public policy. Often times the best way to prevent frustration is to communicate what we know to those who influence and generate health policy. That’s why Friends of Cancer Research is cosponsoring a symposium “The…
There can be confusion and frustration when things we know to be true don’t necessarily mesh with the direction of public policy. Often times the best way to prevent frustration is to communicate what we know to those who influence and generate health policy. That’s why Friends of Cancer Research is cosponsoring a symposium “The…
By NANCI BOMPEY FDA recently made its first breakthrough drug designation but is still grappling with how sponsors will utilize the expedited development pathway that was created as part of the recently enacted FDA Safety and Innovation Act, agency officials revealed this week. The revelation came as stakeholders this week proposed qualitative criteria the agency…
By NANCI BOMPEY FDA recently made its first breakthrough drug designation but is still grappling with how sponsors will utilize the expedited development pathway that was created as part of the recently enacted FDA Safety and Innovation Act, agency officials revealed this week. The revelation came as stakeholders this week proposed qualitative criteria the agency…
By ANDREW POLLACK In an unusual move, a big drug company said on Thursday that it would effectively cut in half the price of a new cancer drug after a leading cancer center said it would not use the drug because it was too expensive. The move — announced by Sanofi for the colon…
By ANDREW POLLACK In an unusual move, a big drug company said on Thursday that it would effectively cut in half the price of a new cancer drug after a leading cancer center said it would not use the drug because it was too expensive. The move — announced by Sanofi for the colon…
By JOHN REICHARD Survivors of certain types of cancer — melanoma, breast, and prostate — report a quality of life similar to that of adults without the disease, according to a new study funded by the National Cancer Institute. But survivors of cervical, blood and colorectal cancers have a lower quality of life. Not surprisingly,…
By JOHN REICHARD Survivors of certain types of cancer — melanoma, breast, and prostate — report a quality of life similar to that of adults without the disease, according to a new study funded by the National Cancer Institute. But survivors of cervical, blood and colorectal cancers have a lower quality of life. Not surprisingly,…
By LISA ROSENBAUM Click HERE to read the full article
